Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Liabilities from Discontinued Operations (2021 - 2025)

Historic Liabilities from Discontinued Operations for Ligand Pharmaceuticals (LGNYZ) over the last 2 years, with Q2 2025 value amounting to $35.7 million.

  • Ligand Pharmaceuticals' Liabilities from Discontinued Operations changed N/A to $35.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $35.7 million, marking a year-over-year change of. This contributed to the annual value of $55.5 million for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q2 2025, Ligand Pharmaceuticals' Liabilities from Discontinued Operations is $35.7 million.
  • In the past 5 years, Ligand Pharmaceuticals' Liabilities from Discontinued Operations ranged from a high of $55.5 million in Q4 2021 and a low of $25.5 million during Q1 2025